Patents Examined by Susan C. Wolski
-
Patent number: 5434051Abstract: An assay for photometrically detecting and/or quantitating the presence of an analyte in a sample in which the signal generated by a label associated with the analyte is photometrically detected in the presence of a suspended solid support.Type: GrantFiled: July 8, 1993Date of Patent: July 18, 1995Assignee: E. I. Du Pont de Nemours and CompanyInventors: William J. Allard, David M. Obzansky, Hermant C. Vaidya
-
Patent number: 5420012Abstract: The invention relates to diagnosis of reactive conditions, such as malignant tumors. According to the invention, the amount of cellular fibronectin in a body fluid is determined, and an elevated amount is used as a marker for a reactive condition. The method is especially suitable for the diagnosis of carcinomas, such as colon carcinoma.Type: GrantFiled: October 23, 1992Date of Patent: May 30, 1995Assignee: Locus Genex OyInventors: Paul Partanen, Sari Ylatupa, Raili Paasivuo, Ismo Virtanen
-
Patent number: 5413913Abstract: In an erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte (in the case of a direct assay) or analyte binding reagent (in the case of an indirect assay). Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.Type: GrantFiled: February 3, 1994Date of Patent: May 9, 1995Assignee: Agen Biomedical, Ltd.Inventors: Carmel J. Hillyard, Dennis B. Rylatt, Bruce E. Kemp, Peter G. Bundesen
-
Patent number: 5405743Abstract: Compounds and methods are disclosed for reversibly aggregating particles suspended in a liquid medium. The method comprises combining the liquid medium containing the particles with a polyionic polymer capable of aggregating the particles under conditions suitable for such aggregation. Thereafter, the particles are contacted with a chemical reagent capable of cleaving the polyionic polymer under conditions sufficient to reverse the aggregation. Optionally, magnetic particles are added to the liquid medium in the present method under conditions for non-specific binding and the medium including the aggregates is subjected to a magnetic field gradient to separate the aggregates from the medium. The compounds of the present invention are polyions. The aggregation of the particles is reversible upon contact with chemical agents which cleave at least some of the bonds within the polyionic polymer.Type: GrantFiled: June 29, 1994Date of Patent: April 11, 1995Assignee: Syntex (U.S.A.) Inc.Inventors: Thomas L. Tarnowski, Cheng-I Lin, Edwin F. Ullman
-
Patent number: 5401636Abstract: An agglutination-based method for detecting and/or an analyte by allowing the agglutination reaction between the analyte, a carrier reagent, and an agglutinating agent to occur in the presence of a multivalent ligand.Type: GrantFiled: November 23, 1993Date of Patent: March 28, 1995Assignee: E. I. Du Pont de Nemours and CompanyInventor: Alan R. Craig
-
Patent number: 5385822Abstract: The presence or quantity of a selected subset of cells, which is part of a subpopulation of a mixed cell population, is determined by a method in which a detectable reporter substance is uniformly incorporated into substantially all cells of the subpopulation containing the subset of interest. The subset of interest is then affinity-separated by incubating a test sample of the mixed cell population containing the labeled subpopulation with a specific binding substance which selectively binds to characteristic determinants of the cell subset of interest. Occurrence of the reporter substance in the separated fraction is then detected, and correlated to a predetermined standard to determine the presence or quantity of the subset of interest within the cell population. According to another aspect of the invention a method is provided for quantitating two or more selected subsets of cells within a subpopulation of a mixed cell population.Type: GrantFiled: November 29, 1990Date of Patent: January 31, 1995Assignee: Zynaxis, Inc.Inventors: Meryle J. Melnicoff, Bruce D. Jensen, Katharine A. Muirhead, Paul K. Horan, Martin D. Summers, William Wong
-
Patent number: 5374529Abstract: Methods of and compositions for early diagnosis, monitoring and treatment of osteoarthritis using monoclonal antibodies which specifically recognize antigenic determinants on atypical chondroitin sulfate/dermatan sulfate glycosaminoglycan chains in body tissues and fluids, which determinants are markers of osteoarthritis.Type: GrantFiled: November 1, 1991Date of Patent: December 20, 1994Inventors: Bruce Caterson, Timothy E. Hardingham
-
Patent number: 5370993Abstract: Compounds and methods are disclosed for reversibly aggregating particles suspended in a liquid medium. The method comprises combining the liquid medium containing the particles with a polyionic polymer capable of aggregating the particles under conditions suitable for such aggregation. Thereafter, the particles are contacted with a chemical reagent capable of cleaving the polyionic polymer under conditions sufficient to reverse the aggregation. Optionally, magnetic particles are added to the liquid medium in the present method under conditions for non-specific binding and the medium including the aggregates is subjected to a magnetic field gradient to separate the aggregates from the medium. The compounds of the present invention are polyions. The aggregation of the particles is reversible upon contact with chemical agents which cleave at least some of the bonds within the polyionic polymer.Type: GrantFiled: May 12, 1992Date of Patent: December 6, 1994Assignee: Syntex (U.S.A.) Inc.Inventors: Thomas L. Tarnowski, Cheng-I Lin, Edwin F. Ullman
-
Patent number: 5369036Abstract: A process for assaying at least one analyte uses a tracer which includes multiple detectable substances. A tracer composition includes at least one ligand labeled with a particulate label, the particulate label containing at least one detectable substance. Two or more detectable substances in the assay may be in the same particulate label or in different particulate labels conjugated to different ligands.Type: GrantFiled: July 2, 1992Date of Patent: November 29, 1994Assignee: Becton, Dickinson and CompanyInventors: Thomas J. Mercolino, Joanne H. Hasskamp, Edward C. McFarland
-
Patent number: 5340748Abstract: Assay reagents, devices, methods and kits used in the analysis of low molecular weight analytes which by themselves are too small or unable to bind to two specific binding members at the same time. The invention involves the use of an analyte-substitute reagent (ASR) comprising at least two components, the first of which is identical to or an analog of the analyte to be determined, while the second is an unrelated ligand for which an antibody or other specific binding member can be obtained or produced.Type: GrantFiled: May 25, 1993Date of Patent: August 23, 1994Assignee: Abbott LaboratoriesInventors: Bennett W. Baugher, Aurora J. Chamberlain, Sharon M. Devereaux, Frank S. Ungemach
-
Patent number: 5330894Abstract: A monoclonal antibody against a procollagenase with a molecular weight of 52000 whose corresponding collagenase cleaves Type I, Type II and Type III collagens, the monoclonal antibody being characterized in, (a) that it belongs to the immunoglobulin class and subclass of G.sub.1 and its L-chain isotype is kappa, and, (b) that it has an inhibitory activity on the collagenase that cleaves Type I, Type II and Type III collagens, and a method for the assay of procollagenase by enzymeimmunoassay utilizing thereof.Type: GrantFiled: September 27, 1991Date of Patent: July 19, 1994Assignee: Kanebo, Ltd.Inventors: Hiroshi Ohmoto, Shintaro Inoue, Seiichi Iwamoto
-
Patent number: 5320944Abstract: An immunoassay method using magnetic particles comprising a core and a coating layer on the surface thereof, The core comprises an organic polymer and the coating layer comprises an iron oxide type ferrite coating layer. An antigen or an antibody is bound onto the surface of the coating layer and the particle has a particle size of 0.2 to 3 .mu.m.Type: GrantFiled: October 22, 1992Date of Patent: June 14, 1994Assignees: Fujirebio Inc., Nippon Paint Co., Ltd.Inventors: Masahisa Okada, Yoshihiro Ashihara, Akira Yano, Masao Oishi, Katsuaki Yoshioka, Toshiomi Nakamura
-
Patent number: 5318914Abstract: The present invention relates to a process for determining or detecting by immuno adherence a biological substance present in a sample, which consists in introducing the sample into a receptacle on whose walls there is a component which has a specific immunological affinity for the substance to be tested for, in adding magnetic particles on which there is a substance which has a specific immunological affinity for the substance to be tested for, in subjecting them to several successive magnetic actions in order to accelerate the deposition of the said particles onto the walls and to displace those which have not formed specific bonds with the substance to be tested for which adheres to the walls via the component with affinity which is fixed thereto, and in observing the particles deposited.Type: GrantFiled: July 21, 1992Date of Patent: June 7, 1994Assignee: Pasteur Sanofi DiagnosticsInventors: Claude Matte, Anne Muller
-
Patent number: 5290678Abstract: A diagnostic test kit is disclosed for assessing whether patient chest pain is cardiac in origin and for differentiating between unstable angina and myocardial infarction at early onset of patient chest pain. The test kit comprises a receptacle for receiving and retaining a sample of blood or serum of the patient and at least three monoclonal or polyclonal antibodies suspended on a carrier. Each antibody is complementary to a different protein released by the heart muscle during early stages of a myocardial infarction and has corresponding reagents which are independently responsive to each antibody reacting the complementary protein. The combined response of reagents indicates the diagnostic condition of the patient.Type: GrantFiled: May 3, 1991Date of Patent: March 1, 1994Assignee: Spectral Diagnostics Inc.Inventor: George Jackowski
-
Patent number: 5270166Abstract: The present invention relates to immunoassay methods for detecting and measuring the amount of an analyte in a sample by means of generic anti-hapten antibodies. Also disclosed are multi-analyte immunoassay methods. Reagents, devices, and kits using the anti-hapten antibodies are also disclosed. The present invention also relates to dyed erythrocytes, preferably fixed, which are coated with antibodies. Also disclosed is the use of these dyed erythrocytes in agglutination assays to detect and measure the presence of an analyte in a sample. The analyte can be a hapten, an antigen, or an antibody. Also included are agglutination assays, compositions and kits using these dyed and coated erythrocytes.Type: GrantFiled: March 30, 1992Date of Patent: December 14, 1993Assignee: Abbott LaboratoriesInventors: Robert Parsons, Robert Kowal, Vincent T. Yue
-
Patent number: 5248589Abstract: An Fc receptor protein conjugated with Ferritin binds to an exposed Fc region of an antibody to form a cell/Ferritin complex. Magnetic particles are added to the medium and bind to the complex. The magnetic particles when bound to the complex significantly enhance the magnetic field gradient of the complex such that it may be separated magnetically from the medium.Type: GrantFiled: January 16, 1992Date of Patent: September 28, 1993Assignee: Board of Governors for Higher Education, State of Rhode Island and Providence PlantationsInventors: Arijit Bose, Srinivas V. Sonti
-
Patent number: 5246869Abstract: The objective of the present invention is a method for determining two or more radioactively labeled ligands simultaneously in the same sample. According to the invention the ligands are determined with proximity assay so that for determining said ligands support materials with different scintillation characteristics are employed, each said support material having attached onto it molecules specifically binding one of said ligands. The support material consists totally or partially of scintillator.Type: GrantFiled: September 23, 1991Date of Patent: September 21, 1993Assignee: Wallac OyInventors: Colin Potter, Gerald Warner, Timo Oikari
-
Patent number: 5238811Abstract: A laser magnetic immunoassay (LMIA) technique is presented which combines the high detection sensitivity of the radioimmunoassay (RIA) technique with the simplicity of particle agglutination (PA) technique. The LMIA technique dispenses with the separation step of bound and free species (B/F separation), yet provides detectivity of the order of picogram of viral species per milliliter of analyte solution. The procedure includes of the steps of: preparing a superparamagnetic-labeled body of antigen or antibody; subjecting a specimen sample and the magnetic-labeled body to a specific immunoreaction to produce a reacted body; subjecting the reacted body containing both bound and free species to a spot magnetic field gradient; irradiating the spot with a laser beam; measuring the intensity of the outgoing light from the spot; and making a quantitative determination of the virus according to the time difference in the outgoing light signals generated by bound and free species.Type: GrantFiled: April 27, 1992Date of Patent: August 24, 1993Assignee: Nippon Telegraph and Telephone CorporationInventors: Koichi Fujiwara, Hiroko Mizutani, Hiromichi Mizutani, deceased, Shuichi Shibata, Koichi Arishima, Mitsutoshi Hoshino, Yasushi Hoshino
-
Patent number: 5236824Abstract: An in-situ laser magnetic immunoassay ("LMIA") method which eliminates the step of B/F separation generally required in the labeling method of immunoassays. The laser magnetic immunoassay permits a quantitative determination of a target immunological substance, for example, an antigen, an antibody, lymphocytes, viruses, tumorous cells and infections cells, in an analyte solution containing both bound and free species. A transitory increase in the magnetophoretic scattering of laser beam is observed when the analyte solution contains magnetic-labeled, bound target analyte, while no such increase is observed in a control test solution, containing only the relevant reagents. A magnetophoretic LMIA apparatus is provided which includes a magnetic gradient generating device which forms an integral part of the in-situ LMIA.Type: GrantFiled: December 18, 1991Date of Patent: August 17, 1993Assignee: Nippon Telegraph and Telephone CorporationInventors: Koichi Fujiwara, Hiroko Mizutani, Hiromichi Mizutani, deceased, Shuichi Shibata, Koichi Arishima, Mitsutoshi Hoshino, Yasushi Hoshino
-
Patent number: 5221613Abstract: A combination of reagents including (i) a first liquid containing (a) first microcapsules having an analyte immobilized on surfaces thereof and containing a marker therein and (b) microcapsules encapsulating an antibody and having different capsule walls from said first analyte immobilized microcapsules with respect to susceptibility to a capsule wall lysin, and (ii) a second liquid containing complement is suitable for immunoassay based on complement-dependent immune lysis of microcapsules.Type: GrantFiled: February 1, 1990Date of Patent: June 22, 1993Assignee: Wako Pure Chemical Industries Ltd.Inventors: Masaaki Kida, Kazunisa Kubotsu, Shuji Matuura